# Imatinib

## Leevk 100mg

| TAH Drug Code      | [OLEEV](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OLEEV)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Used for the treatment of: - Patients with chronic myelogenous leukemia (CML) in the acute transformation phase (blast crisis)， accelerated phase， or chronic phase unresponsive to alpha-interferon therapy. - Treatment of adult patients with malignant gastrointestinal stromal tumors (GISTs) that cannot be surgically removed or are metastatic. - Treatment of patients newly diagnosed with chronic myelogenous leukemia (CML). - Treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. - As a monotherapy for the treatment of adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). - Treatment of adult patients with myelodysplastic syndromes (MDS) or myeloproliferative diseases (MPD) associated with platelet-derived growth factor receptor (PDGFR) gene rearrangement. - Treatment of adult patients with systemic mastocytosis (SM)， limited to those with FIP1L1-PDGFR gene mutation and without the c-Kit gene D816V mutation. - Treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with platelet-derived growth factor receptor (PDGFR) gene rearrangement. - As adjuvant therapy after complete gross resection of adult KIT (CD117)-positive gastrointestinal stromal tumors (GISTs). - Treatment of adult patients with dermatofibrosarcoma protuberans (DFSP) that is unresectable， recurrent， metastatic， and associated with platelet-derived growth factor receptor (PDGFR) gene rearrangement. |
| Dosing             | [Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)]- Chronic phase: 400 mg once daily， may be increased to 600 mg daily- Accelerated phase or blast crisis: 600 mg once daily， may be increased to 800 mg daily (400 mg twice daily) [Ph+ acute lymphoblastic leukemia (ALL)] 600 mg once daily [Myelodysplastic/myeloproliferative disease (MDS/MPD)] 400 mg once daily [Aggressive systemic mastocytosis (ASM) associated with eosinophilia] Initiate at 100 mg once daily; if assessments demonstrate insufficient response， increase from 100-400 mg/day in the absence of adverse reactions. [ASM without D816V c-Kit mutation or c-Kit mutation status unknown] 400 mg once daily [Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL)] 400 mg once daily [HES/CEL with FIP1L1-PDGFRα fusion kinase] Initiate at 100 mg once daily; if assessments demonstrate insufficient response， increase from 100-400 mg/day in the absence of adverse reactions. [Gastrointestinal stromal tumors (GIST)]- Adjuvant treatment following complete resection: 400 mg once daily; recommended treatment duration: 3 years- Unresectable and/or metastatic malignant: 400 mg once daily; may be increased up to 800 mg daily (400 mg twice daily)， if tolerated， for disease progression. [Dermatofibrosarcoma protuberans (DFSP)] 400-800 mg/day (400 mg once or twice daily)                                                                                                                                                                                                                                               |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Contraindications  | Hypersensitivity to imatinib or any component of the formulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Adverse Effects    | GI disturbances， anorexia， gastro-esophageal reflux， mouth ulceration， myalgia， muscle cramps， joint swelling， headache， dizziness， taste disturbance， paraesthesia， insomnia， conjunctivitis， increased lacrimation， blurred vision， epistaxis， dyspnea， weight gain， periorbital edema， dermatitis， rash， face & eyelid edema， pruritus， erythema， dry skin， alopecia， night sweats， fluid retention & edema， fatigue; pyrexia， weakness， rigors; neutropenia & febrile neutropenia， thrombocytopenia， anemia. Cardiovascular: Edema (1.1% to 86.1% ) Dermatologic: Night sweats (13% to 17% )， Rash (up to 49.8% ) Endocrine metabolic: Weight gain (up to 32% ) Gastrointestinal: Diarrhea (3% to 58.2% )， Nausea (3% to 73% )， Vomiting (2% to 58% ) Musculoskeletal: Arthralgia (12.3% to 40% )， Cramp (up to 62% )， Musculoskeletal pain (up to 49% )， Myalgia (9% to 32.2% ) Neurologic: Asthenia (15% to 21% )， Dizziness (12% to 16% )， Headache (up to 36% )， Insomnia (10% to 14% ) Respiratory: Cough (14% to 27% )， Nasopharyngitis (10% to 30.5% )， Pain， Pharyngolaryngeal (18.1% )， Pharyngitis (10% to 15% ) Other: Fatigue (25% to 48% )， Fever (16.7% to 41% )， Influenza (0.8% to 13.8% )， Rigor (10% to 12% )                                                                                                                                                                                                                                                                                                                                                                                     |
| Pregnancy          | Human (and Animal) Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| More Info          | [UpToDate](https://www.uptodate.com/contents/imatinib-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

